Grassmuno

News

Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.